Impact of socioeconomic status on cardiovascular outcomes in Canada
Alter DA, Brandes S, Irvine J, Iron K. Expert Rev Pharmacoecon Outcomes Res. 2003; 3(6):691-702.
Publications
Surgeon volume and operative mortality in the United States
Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. N Engl J Med. 2003; 349(22):2117-27.
Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach
Laupacis A, Paterson JM, Mamdani M, Rostom A, Anderson GM. CMAJ. 2003; 169(11):1167-70.
Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model
Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. JAMA. 2003; 290(19):2581-7.
Prevalence of information gaps in the emergency department and the effect on patient outcomes
Stiell A, Forster AJ, Stiell IG, van Walraven C. CMAJ. 2003; 169(10):1023-8.
What Effects do Provincial Drug Plan Coverage Policies for New Drugs have on Patterns of Use and Cost?
Canadian cardiovascular hospitalization rates and length of stay
Hall R. Healthc Q. 2003; 7(1):22-4.
The use of fixed- and random-effects models for classifying hospitals as mortality outliers: a Monte Carlo assessment
Austin PC, Alter DA, Tu JV. Med Decis Making. 2003; 23(6):526-39.
Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001
Jackevicius CA, Tu K, Filate WA, Brien SE, Tu JV; Canadian Cardiovascular Outcomes Research Team. Can J Cardiol. 2003; 19(12):1359-66.
Evaluation of a community-based inner-city disease management program for postmyocardial infarction patients: a randomized controlled trial
Young W, Rewa G, Goodman SG, Jaglal SB, Cash L, Lefkowitz C, Coyte PC. CMAJ. 2003; 169(9):905-10.